|
| A) | Clopidogrel | ||
| B) | Dabigatran | ||
| C) | Heparin | ||
| D) | Aspirin |
| A) | Edoxaban | ||
| B) | Dabigatran | ||
| C) | Warfarin | ||
| D) | Enoxaparin |
| A) | Rivaroxaban | ||
| B) | Cangrelor | ||
| C) | Warfarin | ||
| D) | Aspirin |
| A) | Warfarin titrated to a goal INR of 2–3 | ||
| B) | Aspirin 81 mg orally daily plus clopidogrel 75 mg orally daily | ||
| C) | Apixaban 5 mg orally twice daily | ||
| D) | Warfarin titrated to a goal INR of 2.5–3.5 |
| A) | Clopidogrel | ||
| B) | Prasugrel | ||
| C) | Ticagrelor | ||
| D) | Cangrelor |
| A) | Stop heparin infusion and begin dabigatran immediately | ||
| B) | Stop heparin infusion and begin dabigatran 12 hours later | ||
| C) | Begin dabigatran and overlap heparin infusion for 6 hours before stopping | ||
| D) | Stop heparin infusion and begin dabigatran 24 hours later |
| A) | Administer a clopidogrel loading dose 2 hours prior to stopping the cangrelor infusion | ||
| B) | Administer a prasugrel loading dose immediately after the cangrelor infusion has been stopped | ||
| C) | Stop the cangrelor infusion and administer a ticagrelor loading dose 12 hours later | ||
| D) | None of the above |
| A) | Heparin infusion | ||
| B) | Rivaroxaban | ||
| C) | Cangrelor infusion | ||
| D) | Dabigatran |
| A) | Extremes of weight (e.g., morbid obesity or low body weight) | ||
| B) | Pregnancy | ||
| C) | Impaired kidney function in patients who cannot receive other anticoagulants | ||
| D) | All of the above |
| A) | Atrial fibrillation | ||
| B) | Primary prevention of atherosclerotic disease | ||
| C) | Noncardioembolic minor stroke (NIHSS score less than or equal to 3) | ||
| D) | Venous thromboembolism |